🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to my son Isaac on his graduation!!! Very proud dad here. lnkd.in/eHNwDxYd

My son Jonathan graduated from Carleton University with his Masters in Journalism. Congratulations Jonathan!! Very proud. lnkd.in/ektY6-pj

The Regenerative Medicine Program at the Ottawa Hospital Research Institute has multiple Faculty Positions open for recruitment!!!!! lnkd.in/g_78UmAi

Great news and important milestone to bring our lead drug candidate for Duchenne into clinical trials!

Another important milestone for SAT-3247, our lead drug candidate in #Duchenne #musculardystrophy! #raredisease #rarediseases #PRV

Happy to share more from the large animal study of SAT-3247, our lead drug candidate in #Duchenne #musculardystrophy. These are important data in confirming the improved muscle regeneration and muscle function that we’ve seen in the mdx mouse models after treatment with SAT-3247.

Today, we are excited to announce the acceptance of our regulatory filing that allows us to begin our Phase 1 clinical trial with SAT-3247. We look forward to beginning enrollment in the study and dosing our first participant. Read the release for more details:

Our CEO Frank Gleeson spoke with Clinical Trials Arena about the details of our upcoming #clinicaltrials for SAT-3247, which we are developing as a novel #smallmolecule medicine for #Duchenne #musculardystrophy. Read the article here: clinicaltrialsarena.com/news/satellos-… #raredisease #rarediseases

This interview showcases not only the science behind Satellos Bioscience, but also the determination Frank Gleeson and I share to provide new hope for those who live valiantly with Duchenne muscular dystrophy and other degenerative muscle diseases. Well worth the listen!

Satellos Co-founder and CEO Frank Gleeson will be speaking at the @DefeatDuchenne Family Forum, a national education program specifically designed for families living with Duchenne muscular dystrophy. Frank will discuss the company’s lead drug candidate that is designed to

It's incredibly rewarding to see years of research progress to this milestone. The first participant has been dosed in the Phase 1 clinical study of SAT-3247! This brings us one step closer to changing how #Duchenne #musculardystrophy is treated. #ScienceInAction

Exciting data from the SAT-3247 study in a canine model of Duchenne!

When you're designing a drug for a patient population that is severely compromised or facing additional challenges, efficacy isn't the only consideration. The end goal is an easy to administer medication with a benign side effect profile that could fit well into a full regimen of

I encourage anyone in the stem cell and regenerative medicine community in the Montreal area (and beyond!) who is thinking about how to commercialize their research, launch a new-co, or attract private investment to attend this half-day symposium. #TMM2024

Over a decade ago, my lab’s research on muscle stem cells opened a new understanding of #Duchenne muscular dystrophy. Seeing how it led to a drug now in clinical trials with Satellos Bioscience is deeply rewarding. Thanks to Ottawa Citizen for highlighting this milestone!

Excited to represent Satellos at the Duchenne KOL Investor Webinar on Wednesday and share the science behind our mission to transform Duchenne muscular dystrophy treatment!

I’m excited to speak today at the Duchenne KOL Investor Webinar about the science behind SAT-3247 and its potential to transform treatment for #Duchenne #musculardystrophy. Join us for this important conversation. 🕒 Today, 2pm ET 🔗 ir.satellos.com/news/news-deta… $MSCL.to $MSCLF

From vision to reality: the first #Duchenne participant has been dosed in our Phase 1b trial of SAT-3247. This milestone reflects Satellos Bioscience's mission to advance therapies restoring muscle regeneration. Grateful to our team and supporters for making this possible.

It’s an honour to see that the impact of my early research into satellite cells continues to resonate in the field. I’m looking forward to seeing it translate into patients as our work at Satellos Bioscience progresses in clinical trials.

Great article on the science behind SAT-3247, a potential breakthrough for #Duchenne muscular dystrophy. Developed from our research on muscle stem cell regeneration, this oral drug could restore muscle repair where it’s most needed.